{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:26:09Z","timestamp":1783329969076,"version":"3.54.6"},"reference-count":81,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background\/Objectives: Omalizumab is an effective treatment for antihistamine-refractory chronic urticaria. However, post-injection urticaria exacerbation and related adverse reactions remain inconsistently reported. This scoping review mapped evidence on clinical presentation, timing, mechanisms, management strategies, rechallenge outcomes, treatment discontinuation, and patient outcomes associated with these reactions. Methods: The review followed the Joanna Briggs Institute methodology and was registered prospectively in INPLASY (INPLASY202650060). PubMed, Scopus, and the Directory of Open Access Journals were searched from inception to April 2026. Eligible studies included English-language case reports, case series, observational studies, cohort studies, registry or pharmacovigilance studies, postmarketing surveillance studies, and clinical trials reporting urticaria-related or hypersensitivity-type adverse reactions during omalizumab treatment for chronic urticaria. Data were charted descriptively and synthesized narratively. Results: Seventeen studies published between 2015 and 2026 included 2790 patients with chronic urticaria, 60 of whom experienced urticaria-related adverse reactions, corresponding to a mapped proportion of 2.2%. Clinical phenotypes included transient urticaria exacerbation, urticaria flare or worsening, localized urticarial plaques at the injection area, angioedema, anaphylaxis or anaphylaxis-like reactions, and serum sickness-like reactions. Reactions occurred within minutes to several hours, within 24 h, several days, or up to 1 week after injection or dose escalation. Reactions occurred following the first dose, repeated doses, and dose escalation. Proposed mechanisms included delayed hypersensitivity, possible IgE-mediated delayed-onset anaphylaxis, serum sickness-like reaction, paradoxical worsening, infection-associated flare, excipient-related reactions, and severe underlying CSU exacerbation mimicking anaphylaxis. Management strategies ranged from observation or symptomatic treatment to discontinuation of omalizumab and systemic interventions. Conclusions: Omalizumab-associated urticaria-related adverse reactions were infrequently reported across the mapped evidence but were clinically heterogeneous. Standardized definitions and detailed case reporting are needed to clarify causality, recurrence risk, rechallenge safety, and long-term outcomes.<\/jats:p>","DOI":"10.3390\/life16071124","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:05:38Z","timestamp":1783325138000},"page":"1124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-7323","authenticated-orcid":false,"given":"Weeratian","family":"Tawanwongsri","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand"},{"name":"Center of Excellence in Data Science for Health Study, Walailak University, Nakhon Si Thammarat 80160, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitchaya","family":"Jaruvijitrattana","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal Medicine, Chaophya Abhaibhubejhr Hospital, Prachin Buri 25000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chime","family":"Eden","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jigme Dorji Wangchuck National Referral Hospital (JDWNRH), Thimphu 11001, Bhutan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: A review","volume":"332","author":"Kolkhir","year":"2024","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Huang, Y., Chen, D., and Wang, Y. (2025). Global health implications of urticaria burden (1990\u20132021): A comprehensive analysis of trends across nations and regions. Arch. Med. Sci.","DOI":"10.5114\/aoms\/202415"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjd.19561","article-title":"The global burden of chronic urticaria for the patient and society","volume":"184","author":"Bernstein","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zuberbier, T., Abdul Hameed Ansari, Z., Abdul Latiff, A.H., Abuzakouk, M.M., Agcaoili-De Jesus, M.S., Agondi, R.C., Al-Ahmad, M., Alangari, A.A., Alhameli, H., and Alonso Bello, C.D. (2026). The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 1\u201351.","DOI":"10.1111\/all.70210"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab Updosing in Chronic Spontaneous Urticaria: An Overview of Real-World Evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjd.13074","article-title":"Commentary: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"171","author":"Sabroe","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-200161020-00008","article-title":"Omalizumab","volume":"61","author":"Easthope","year":"2001","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","article-title":"Omalizumab for patients with chronic spontaneous urticaria: A narrative review of current status","volume":"13","author":"Casale","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1097\/MJT.0000000000000912","article-title":"Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"27","author":"Jia","year":"2020","journal-title":"Am. J. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","first-page":"82","article-title":"Adverse reaction to omalizumab in patients with chronic urticaria: Flare up or ineffectiveness?","volume":"15","author":"Yildiz","year":"2016","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.alit.2022.09.003","article-title":"Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study","volume":"72","author":"Hide","year":"2023","journal-title":"Allergol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2147\/CCID.S470160","article-title":"Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome","volume":"17","author":"Chen","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cea.70067","article-title":"Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World Study","volume":"55","author":"Soegiharto","year":"2025","journal-title":"Clin. Exp. Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.11124\/JBIES-20-00570","article-title":"Methodological quality, guidance, and tools in scoping reviews: A scoping review protocol","volume":"20","author":"Pollock","year":"2022","journal-title":"JBI Evid. Synth."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.4103\/jfmpc.jfmpc_831_21","article-title":"Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions","volume":"10","author":"Shukla","year":"2021","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13204","DOI":"10.1111\/dth.13204","article-title":"A severe adverse reaction to omalizumab therapy in chronic spontaneous urticaria","volume":"33","author":"Dies","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/pai.12877","article-title":"Serum sickness-like reaction in a pediatric patient using omalizumab for chronic spontaneous urticaria","volume":"29","author":"Eapen","year":"2018","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_21","first-page":"e135","article-title":"Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria","volume":"30","author":"Ergin","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","first-page":"e61453","article-title":"Paradoxical Worsening of Chronic Spontaneous Urticaria Following Omalizumab Administration: The Missing Link","volume":"16","author":"Konstantinou","year":"2024","journal-title":"Cureus"},{"key":"ref_23","first-page":"1587","article-title":"Serum sickness-like reaction after omalizumab administration: A case report and short literature review","volume":"23","author":"Lestani","year":"2025","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/ced.13616","article-title":"Development of angio-oedema after omalizumab injections in a patient with chronic spontaneous urticaria","volume":"43","author":"Magen","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E912","DOI":"10.1093\/milmed\/usz357","article-title":"A Case of Serum Sickness-Like Reaction in an Adult Treated with Omalizumab","volume":"185","author":"Weiss","year":"2020","journal-title":"Mil. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/jdv.15684","article-title":"A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: A real-world study in Belgium","volume":"34","author":"Lapeere","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21911\/aai.647","article-title":"Omalizumab in Practice: Ten-Year Experience of A Tertiary Referral Allergy Centre","volume":"20","author":"Demir","year":"2022","journal-title":"Asthma Allergy Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-015-0088-7","article-title":"Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care","volume":"11","author":"Savic","year":"2015","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_29","first-page":"41","article-title":"Efficacy of omalizumab in treatment-resistant chronic spontaneous urticaria","volume":"17","year":"2019","journal-title":"Asthma Allergy Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000545336","article-title":"The Efficacy of Different Dosing Regimens of Omalizumab in Children and Adolescents with Chronic Spontaneous Urticaria Based on Real-Life Data","volume":"187","author":"Cekic","year":"2026","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Galletta, F., Caminiti, L., Lugar\u00e0, C., Foti Randazzese, S., Barraco, P., D\u2019Amico, F., Irrera, P., Crisafulli, G., and Manti, S. (2023). Long-Term Safety of Omalizumab in Children with Asthma and\/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life. J. Pers. Med., 13.","DOI":"10.3390\/jpm13071068"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/1744666X.2020.1724089","article-title":"Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases","volume":"16","author":"Jackson","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jaip.2022.09.038","article-title":"Existing and investigational medications for refractory chronic spontaneous urticaria: Safety, adverse effects, and monitoring","volume":"10","author":"Kocaturk","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e15117","DOI":"10.1111\/dth.15117","article-title":"Dupilumab-induced Urticaria","volume":"34","author":"Mastorino","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"AB12","DOI":"10.1016\/j.jaci.2020.12.088","article-title":"Delayed onset localized urticarial reactions to dupilumab","volume":"147","author":"Xu","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/pde.14434","article-title":"Angioedema: A potential complication of dupilumab in atopic dermatitis","volume":"38","author":"Fritz","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1159\/000548302","article-title":"Safety and Efficacy of Remibrutinib for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis","volume":"187","author":"Burhan","year":"2025","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4103\/ds.DS-D-25-00174","article-title":"Immune checkpoint inhibitor-related urticaria characterized by a distinct autoimmune and autoallergic signatures","volume":"43","author":"Chen","year":"2025","journal-title":"Dermatol. Sin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1159\/000515500","article-title":"Evaluation of hypersensitivity reactions in pediatric patients using biological drugs","volume":"182","author":"Kose","year":"2021","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/ACI.0000000000000550","article-title":"Biologics and anaphylaxis","volume":"19","author":"Luengo","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/ACI.0b013e3283464bcd","article-title":"Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management","volume":"11","author":"Vultaggio","year":"2011","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jaip.2021.04.023","article-title":"Triggers of exacerbation in chronic urticaria and recurrent angioedema\u2014Prevalence and relevance","volume":"9","author":"Grumach","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","first-page":"833","article-title":"Treatment satisfaction in chronic urticaria during guideline-based therapy","volume":"19","author":"Berndt","year":"2021","journal-title":"JDDG J. Ger. Soc. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaip.2016.09.029","article-title":"Prevalence of Inducible Urticaria in Patients with Chronic Spontaneous Urticaria: Associated Risk Factors","volume":"5","author":"Amaya","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_47","unstructured":"Genentech, I. (2024). XOLAIR (Omalizumab) Injection, for Subcutaneous Use, U.S. Food and Drug Administration. Reference ID: 5330389."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1440-1797.2005.00389.x","article-title":"Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin","volume":"10","author":"Steele","year":"2005","journal-title":"Nephrology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0148607111399288","article-title":"Parenteral nutrition\u2013induced hypersensitivity in an adolescent","volume":"36","author":"Bartels","year":"2012","journal-title":"J. Parenter. Enter. Nutr."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1016\/j.xphs.2018.07.016","article-title":"Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants?","volume":"107","author":"Singh","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.18176\/jiaci.0562","article-title":"Delayed hypersensitivity reactions caused by drug excipients: A literature review","volume":"30","author":"Caballero","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1081-1206(10)61024-1","article-title":"Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions","volume":"95","author":"Coors","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: A review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13223-016-0172-7","article-title":"Polyethylene glycol as a cause of anaphylaxis","volume":"12","author":"Wylon","year":"2016","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1398-9995.2006.01265.x","article-title":"Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycols","volume":"62","author":"Demoly","year":"2007","journal-title":"Allergy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2500\/aap.2016.37.3915","article-title":"Association between urticaria and virus infections: A systematic review","volume":"37","author":"Imbalzano","year":"2016","journal-title":"Allergy Asthma Proc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00403-023-02564-y","article-title":"Analysis of clinical features and inflammatory-related molecules with the disease in acute infectious urticaria","volume":"315","author":"Liu","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.0736-8046.2004.21202.x","article-title":"The etiology of different forms of urticaria in childhood","volume":"21","author":"Sackesen","year":"2004","journal-title":"Pediatr. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00130832-200410000-00010","article-title":"Chronic urticaria and infections","volume":"4","author":"Wedi","year":"2004","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000450953","article-title":"Parasitic infections in children with chronic spontaneous urticaria","volume":"171","author":"Karaatmaca","year":"2016","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/all.12818","article-title":"Chronic spontaneous urticaria and internal parasites\u2014A systematic review","volume":"71","author":"Kolkhir","year":"2016","journal-title":"Allergy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1440-1592.2004.00354.x","article-title":"A case of chronic urticaria due to Dirofilaria infestation","volume":"53","author":"Matucci","year":"2004","journal-title":"Allergol. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2500\/aap.2018.38.4104","article-title":"Association between urticaria and nematode infections","volume":"39","author":"Minciullo","year":"2018","journal-title":"Allergy Asthma Proc."},{"key":"ref_65","first-page":"117","article-title":"Chronic urticaria and Blastocystis hominis infection. A case report","volume":"8","author":"Pasqui","year":"2004","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bracken, S.J., Abraham, S., and MacLeod, A.S. (2019). Autoimmune theories of chronic spontaneous urticaria. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00627"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: Associations found in a large population study","volume":"129","author":"Chodick","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cea.12673","article-title":"Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus\u2014A systematic review","volume":"46","author":"Kolkhir","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/all.12030","article-title":"How not to miss autoinflammatory diseases masquerading as urticaria","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/CRIAI:30:1:019","article-title":"Drug-induced urticarias","volume":"30","year":"2006","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2332\/allergolint.12-RAI-0493","article-title":"Recent advances in drug-induced angioedema","volume":"61","author":"Inomata","year":"2012","journal-title":"Allergol. Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2015.06.021","article-title":"Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug\u2013related urticaria and angioedema","volume":"136","author":"Kowalski","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/1742-6723.13781","article-title":"Acute dystonic reaction mimicking angioedema secondary to metoclopramide ingestion","volume":"33","author":"Fong","year":"2021","journal-title":"Emerg. Med. Australas."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1157\/13112996","article-title":"Not all ACE inhibitor related angioedema is always evident: A case which is misdiagnosed as panic attack and speech disorder","volume":"35","author":"Gulec","year":"2007","journal-title":"Allergol. Immunopathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: A critical review","volume":"9","author":"Akin","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1710-1492-6-32","article-title":"Omalizumab: Practical considerations regarding the risk of anaphylaxis","volume":"6","author":"Kim","year":"2010","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13555-018-0240-7","article-title":"Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies","volume":"8","author":"Mandel","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1590\/abd1806-4841.20187074","article-title":"Urticaria and angioedema as possible reactions of omalizumab","volume":"93","author":"Ozbagcivan","year":"2018","journal-title":"Bras. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/jcpt.12827","article-title":"Rapid subcutaneous desensitization for the management of delayed hypersensitivity reactions to omalizumab: A case report","volume":"44","author":"Gan","year":"2019","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:12:28Z","timestamp":1783329148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":81,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["life16071124"],"URL":"https:\/\/doi.org\/10.3390\/life16071124","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}